Drugs / AG-236
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07075640 | Jul 2025 → Feb 2026 overdue | — | Agios Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-07-31 | Agios Pharmaceuticals, Inc. | Regulatory Agios Reports Second Quarter 2025 Financial Results and Provides Business Update agios.com ↗
Dosed first patient in the tebapivat Phase 2 sickle cell disease trial and received IND clearance for AG-236 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-07-31 | Agios Pharmaceuticals, Inc. | Agios Reports Second Quarter 2025 Financial Results and Provides Business Update agios.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AG-236 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07075640 ↗ |
| Route | Subcutaneous | “AG-236 administered subcutaneously” NCT07075640 ↗ |